Helix BioPharma (OTCMKTS:HBPCF) Shares Down 11.6% – Should You Sell?

Shares of Helix BioPharma Corp. (OTCMKTS:HBPCF – Get Free Report) dropped 11.6% during mid-day trading on Tuesday . The company traded as low as $0.65 and last traded at $0.65. Approximately 2,900 shares changed hands during trading, an increase of 136% from the average daily volume of 1,228 shares. The stock had previously closed at $0.74.

Helix BioPharma Stock Performance

The firm has a market cap of $134.81 million, a P/E ratio of -32.50 and a beta of 0.02. The company’s 50 day moving average is $0.86 and its 200 day moving average is $0.41.

About Helix BioPharma

(Get Free Report)

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.

Recommended Stories

• Five stocks we like better than Helix BioPharma
• 2 Fintech Stocks to Buy Now and 1 to Avoid
• Microsoft Can Hit New All-Time Highs This Year – Here’s Why
• Using the MarketBeat Stock Split Calculator
• Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
• Conference Calls and Individual Investors
• IonQ’s Quantum Surge: Ride the Wave or Cash Out?